Over the past week, a few biotech companies made impressive runs. These moves were the result of clinical trial results, U.S. Food and Drug Administration (FDA) decisions and more. The companies 24/7 Wall St. has picked stood out from the rest with positive news guiding them last week. We have included information about each company, as well as recent trading activity and the consensus price target.

Relypsa

After news broke that Relypsa Inc. (NASDAQ: RLYP) might be pursuing a sale, the company watched its shares absolutely take off about halfway through Thursday’s trading session. Reuters reported that Relypsa is said to be in talks with Centerview Partner Holdings to review offers. Although these discussions are only in the early stages, there might not actually be a sale.

Shares of Relypsa rose 79% over the course of the week. Year to date, the shares are down around 14%. The stock closed Friday at $22.48. The consensus analyst price target is $38.64, and the 52-week trading range is $10.26 to $37.95.

Valeant Pharmaceuticals

Valeant Pharmaceuticals International Inc. (NYSE: VRX) is continuing to bounce back from a devastating first quarter. This embattled company received positive news in the middle of the week that it would be allowed to amend the terms of its debt, effectively buying more time to fix itself. Some investors might be brave enough to call this a bottom as well.

During the week, Valeant shares rose 35%. But they are down 65% year to date. The stock closed Friday at $33.67. It has a consensus price target of $64.61 and a 52-week range of $25.27 to $263.81.

Celator Pharmaceuticals

Over the past week, Celator Pharmaceuticals Inc. (NASDAQ: CPXX) has surged on positive momentum. The company recently announced the pricing of its secondary offering of 4 million shares for $9.50 per share. This oncology-focused biopharmaceutical company is transforming the science of combination therapy and developing products to improve patient outcomes in cancer. Its proprietary technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver enhanced anti-cancer activity.

Last week, Celator shares rose 25%. Year to date, they are up almost 700%. The stock ended the week at $12.98. The consensus analyst target is $18.33, and the 52-week range is $1.12 to $13.90.

Raptor Pharmaceuticals

Like Relypsa, Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) is reportedly exploring a potential sale. As previously stated, although the company may be in talks with investment banks now, it is still very much a possibility that a sale might not happen.

Raptor stock is up year to date 7%. Over the past week, shares rose 21%. The stock last traded at $5.44. The stock has a consensus price target of $7.33 and a 52-week range of $2.94 to $16.28.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.